Commencement of Commercial Production at IV Fluid Infusion Plant
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanjivani Paranteral Ltd's subsidiary, SPL Infusion Pvt. Ltd., has started commercial production at its newly set up IV Fluid Infusion Plant in Pune, Maharashtra, effective 6th September 2025. The facility received the necessary manufacturing license from regulatory authorities before commencing operations. The plant is strategically located near major pharmaceutical clusters and hospitals, enabling the company to serve both domestic and export markets. The facility features modern plant and machinery along with solar panels aimed at lowering long-term operating costs. The company describes this as a key milestone that opens a new revenue vertical and strengthens its position in pharmaceutical manufacturing.
Positive for shareholders as it signals entry into a new revenue stream and expanded manufacturing capacity, though actual financial contribution will depend on how quickly the plant ramps up utilisation and secures customers.